Worth reading
47Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-19.6
% (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales788,960¥ millionYear on year +4.1%Progress 25.1%
Operating profit5,596¥ millionYear on year -19.6%Progress 16.5%
Ordinary income6,088¥ millionYear on year -20.5%Progress 16.6%
Net income attributable to owners of the parent2,476¥ millionYear on year -50.5%Progress 11.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥13.85
Financial position at period-end
Total assets1,509,704¥ million
of which net assets 486,328 ¥ millionEquity ratio 32.2%vs. prior year-end -1.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueWholesale business for prescription pharmaceuticals and other products ¥709,803 million (YoY +4.6%), Self-medication products wholesale business ¥66,171 million (YoY -1.1%), Pharmaceuticals and other products manufacturing business ¥11,957 million (YoY -5.3%), Dispensing pharmacy and other businesses ¥9,436 million (YoY +3.6%), Other ¥614 million
Segment profitWholesale business for prescription pharmaceuticals and other products ¥6,622 million (YoY -0.2%), Self-medication products wholesale business ¥537 million (YoY -40.4%), Pharmaceuticals and other products manufacturing business ¥-618 million, Dispensing pharmacy and other businesses ¥-498 million, Other ¥-374 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥3,144,000 million (YoY +1.3%)
Operating profit¥33,900 million (YoY -6.3%)
Ordinary income¥36,600 million (YoY -5.3%)
Net income¥20,800 million (YoY -50.2%)
Annual Dividend Forecast¥68 → ¥71（+4.4%）
Factors Behind Changes in Business Performance
Although sales increased due to higher sales of certain type 2 diabetes treatments and specialty pharmaceuticals, among other products, profit declined as a result of the negative impact of drug price revisions, higher distribution and labor costs, depreciation expenses related to the newly constructed manufacturing facility, and lower sales from active pharmaceutical ingredient manufacturing.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name ArkMS株式会社 / Excluded Not disclosed / Material changes No
Impairment loss¥15 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥36 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥102 million, Impairment Losses ¥15 million, Impairment loss on investment securities ¥750 million, Loss on extinguishment of shares held in a merger ¥151 million
Depreciation and amortization¥4,023 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End191,300,000 shares
Treasury Shares at Period-End15,886,528 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥788,960 million (YoY +4.1%) |
| Operating profit | ¥5,596 million (YoY -19.6%) |
| Ordinary income | ¥6,088 million (YoY -20.5%) |
| Profit attributable to owners of the parent | ¥2,476 million (YoY -50.5%) |
| Net income per share | ¥13.85 |
| Equity ratio | End of the current fiscal period 32.2% / End of previous period 33.7% |
| Total assets | ¥1,509,704 million |
| Net assets | ¥486,328 million |
| Full-year earnings forecast | Net Sales ¥3,144,000 million (YoY +1.3%) / Operating profit ¥33,900 million (YoY -6.3%) / Ordinary income ¥36,600 million (YoY -5.3%) / Net income ¥20,800 million (YoY -50.2%) |
| Annual Dividend Forecast | ¥68 → ¥71（+4.4%） |
| Segment revenue | Wholesale business for prescription pharmaceuticals and other products ¥709,803 million (YoY +4.6%), Self-medication products wholesale business ¥66,171 million (YoY -1.1%), Pharmaceuticals and other products manufacturing business ¥11,957 million (YoY -5.3%), Dispensing pharmacy and other businesses ¥9,436 million (YoY +3.6%), Other ¥614 million |
| Segment profit | Wholesale business for prescription pharmaceuticals and other products ¥6,622 million (YoY -0.2%), Self-medication products wholesale business ¥537 million (YoY -40.4%), Pharmaceuticals and other products manufacturing business ¥-618 million, Dispensing pharmacy and other businesses ¥-498 million, Other ¥-374 million |
| Depreciation and amortization | ¥4,023 million |
| Impairment loss | ¥15 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥36 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥102 million, Impairment Losses ¥15 million, Impairment loss on investment securities ¥750 million, Loss on extinguishment of shares held in a merger ¥151 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name ArkMS株式会社 / Excluded Not disclosed / Material changes No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 191,300,000 shares |
| Treasury Shares at Period-End | 15,886,528 shares |
| Factors Behind Changes in Business Performance | Although sales increased due to higher sales of certain type 2 diabetes treatments and specialty pharmaceuticals, among other products, profit declined as a result of the negative impact of drug price revisions, higher distribution and labor costs, depreciation expenses related to the newly constructed manufacturing facility, and lower sales from active pharmaceutical ingredient manufacturing. |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although sales increased due to higher sales of certain type 2 diabetes treatments and specialty pharmaceuticals, profit declined as a result of the negative impact of drug price revisions, higher distribution and labor costs, and depreciation expenses related to the newly constructed manufacturing facility.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.